These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37546414)

  • 1. Identification and comprehensive analysis of epithelial-mesenchymal transition related target genes of miR-222-3p in breast cancer.
    Fang Y; Zhang Q; Chen C; Chen Z; Zheng R; She C; Zhang R; Wu J
    Front Oncol; 2023; 13():1189635. PubMed ID: 37546414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.
    Fang Y; Zhang Q; Chen Z; Guo C; Wu J
    Aging (Albany NY); 2024 Jan; 16(1):322-347. PubMed ID: 38189813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.
    Pan X; Hong X; Lai J; Cheng L; Cheng Y; Yao M; Wang R; Hu N
    Front Oncol; 2020; 10():441. PubMed ID: 32426266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Serum miR-501-3p and miR-338-3p as Novel Diagnostic Biomarkers for Breast Cancer and Their Target Genes Associated with Immune Infiltration.
    Yin L; Ding Y; Wang Y; Wang C; Sun K; Wang L
    Int J Gen Med; 2023; 16():1279-1294. PubMed ID: 37077765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
    Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
    Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-328-3p inhibits the tumorigenesis of bladder cancer through targeting ITGA5 and inactivating PI3K/AKT pathway.
    Yan T; Ye XX
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5139-5148. PubMed ID: 31298367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
    Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
    BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
    Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
    Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-372-3p promotes the epithelial-mesenchymal transition in breast carcinoma by activating the Wnt pathway.
    Fan X; Huang X; Li Z; Ma X
    J BUON; 2018; 23(5):1309-1315. PubMed ID: 30570852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC01433/miR-2116-3p/MYC Feedback Loop Promotes Cell Proliferation, Migration, and the Epithelial-Mesenchymal Transition in Breast Cancer.
    Wu M; Wu W; Ding J; Yang J
    Cancer Biother Radiopharm; 2019 Aug; 34(6):388-397. PubMed ID: 30939038
    [No Abstract]   [Full Text] [Related]  

  • 11. lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA.
    Lv M; Zhong Z; Huang M; Tian Q; Jiang R; Chen J
    Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1887-1899. PubMed ID: 28779971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-337-3p suppresses migration and invasion of breast cancer cells by downregulating ESRP1.
    Pan Y; Zhao Y; Lihui L; Xie Y; Zou Q
    Acta Histochem; 2021 Oct; 123(7):151777. PubMed ID: 34481218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer.
    Wang JR; Liu B; Zhou L; Huang YX
    Cancer Biomark; 2019; 24(2):159-172. PubMed ID: 30614803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression levels and clinical values of miR-92b-3p in breast cancer.
    Du Y; Miao Z; Wang K; Lv Y; Qiu L; Guo L
    World J Surg Oncol; 2021 Aug; 19(1):239. PubMed ID: 34380511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test.
    Li R; Xia Y; Chen X; Li X; Huang G; Peng X; Liu K; Zhang C; Li M; Lin Y; Dong J; Ji L; Lai Y
    Transl Cancer Res; 2022 May; 11(5):1005-1016. PubMed ID: 35706801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora-A.
    Cui S; Zhang K; Li C; Chen J; Pan Y; Feng B; Lu L; Zhu Z; Wang R; Chen L
    Oncotarget; 2016 Nov; 7(47):78009-78028. PubMed ID: 27793005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomal miR-22-3p from Mesenchymal Stem Cells Inhibits the Epithelial-Mesenchymal Transition (EMT) of Melanoma Cells by Regulating
    Chen Y; Fang Y; Li L; Luo H; Cao T; Tu B
    Front Biosci (Landmark Ed); 2022 Sep; 27(9):275. PubMed ID: 36224027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibitive effect of sh-HIF1A-AS2 on the proliferation, invasion, and pathological damage of breast cancer via targeting miR-548c-3p through regulating HIF-1α/VEGF pathway in vitro and vivo.
    Guo X; Lee S; Cao P
    Onco Targets Ther; 2019; 12():825-834. PubMed ID: 30774370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in breast cancer.
    Zhang L; Chen X; Liu B; Han J
    Oncol Lett; 2018 Jan; 15(1):984-990. PubMed ID: 29387242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of miR-330-3p: a novel independent indicator of poor prognosis in human breast cancer.
    Wang H; Chen SH; Kong P; Zhang LY; Zhang LL; Zhang NQ; Gu H
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1726-1730. PubMed ID: 29630118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.